Inflammation and Alzheimer's disease pathogenesis

Neurobiology of Aging

Volumn 17, Issue 5, 1996, Pages 681-686

  Rogers, Joseph ^a   Webster, Scott ^b   Lue, Lih Fen ^b   Brachova, Libuse ^b   Civin, W Harold ^b   Emmerling, Mark ^b   Shivers, Brenda ^b   Walker, Douglas ^b   McGeer, Patrick ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Alzheimer's disease; Complement; Cytokines; Dementia; Inflammation; Neurodegeneration

Indexed keywords

CYTOKINE;

ALZHEIMER DISEASE; COMPLEMENT ACTIVATION; DEMENTIA; HUMAN; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0030250567     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-4580(96)00115-7     Document Type: Article

References (100)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501; 1988.
2. 1-Antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Neurobiol. Aging 11:123-129; 1990.
3. 3. Akiyama, H.; Ikeda, K.; Kondo, H.; McGeer, P. L. Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci. Lett. 146:152-154; 1992.
4. 4. Akiyama, H.; Kawamata, T.; Dedhar, S.; McGeer, P. L. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J. Neuroimmunol. 32:19-28; 1991.
5. 5. Akiyama, H.; McGeer, P. L. Brain microglia constituvely express β-2 integrins. J. Neuroimmunol. 30:81-93; 1990.
6. 6. Andersen, K.; Launer, L. J.; Ott, A.; Hoes, A. W.; Breteler, M. M. B.; Hofman, A. Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer's disease? Neurology 45:1441-1445; 1995.
7. 7. Araujo, D.M.; Cotman, C. W. β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res. 569:141-145; 1992.
8. 2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285:111-114; 1991.
9. 9. Benzing, W. C.; Brady, D. R.; Mufson, E. J.; Armstrong, D. M. Evidence that transmitter-containing dystrophic neurites precede those containing paired helical filaments within senile plaques in the entorhinal cortex of nondemented elderly and Alzheimer's disease patients. Brain Res. 619:55-68; 1993.
10. 10. Brachova, L.; Lue, L.-F.; Byttner, S.; Sue, L.; Civin, W. H.; Shultz, J.; Tuohy, J.; Rogers, J. Reduced complement activation in nondemented patients with excessive β-amyloid peptide deposition. Soc. Neurosci. Abstr. 19:833; 1993.
11. 11. Brachova, L.; Lue, L.-F.; Schultz, J.; El Rashidy, T.; Rogers, J. Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Mol. Brain Res. 18:329-334; 1993.
12. 12. Breitner, J. C. S.; Gau, B. A.; Welsh. K. A.; Plassman, B. L.; McDonald, W. M.; Helmas, M. J.; Anthony, J. C. Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 44:227-232; 1994.
13. 13. Breitner, J. C. S.; Welsh, K. A.; Helms, M. J.; Gaskell, P. C.; Gau, B. A.; Roses, A. D.; Pericak-Vance, M. A.; Saunders, A. M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16:523-520; 1995.
14. 14. Broe, G. A.; Henderson, A. S.; Creasey, H.; McCusker, E.; Korten, H. E.; Jorm, A. F.; Longley, W.; Anthony, J. C. A case-control study of Alzheimer's disease in Australia. Neurology 40:1698-1707; 1990.
15. 15. Buxbaum, J. D.; Oishi, M.; Chen, H. I.; Pinkas-Kramarski, R.; Jaffe, E. A.; Gandy, S. E.; Greengard, P. Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 89:10075-10078; 1992.
16. 16. Cacabelos, R.; Alvarez, X. A.; Fernandez-Novoa, L.; Franco A.; Mangues, R.; Pellicer, A.; Nishimura, T. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find. Exp. Clin. Pharmacol. 16:141-145; 1994.
17. 17. Canadian Study of Health and Aging. Risk factors for Alzheimer's disease in Canada. Neurology 44:2073-2080; 1994.
18. 18. Choi-Miura, N.-H.; Ihara, Y.; Fukuchi, K.; Takeda, M.; Nakano, Y.; Tobe, T.; Tomita, M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. 83:260-264; 1992.
19. 19. Coria, F.; Castano, E.; Prelli, F.; Larrondo-Lillo, M.; van Duinen, S.; Shelanski, M. L.; Frangione, B. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab. Invest. 58:454-458; 1988.
20. 20. Duguid, J. R.; Bohmont, C. W.; Liu, N.; Tourtellotte, W. W. Changes in gene expression shared by scrapie and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86:7260-7264; 1989.
21. 21. Duong, T.; Pommier, E. C.; Schiebel, A. B. Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathol. 78:429-437; 1989.
22. 22. Eikelenboom, P.; Hack, C. E.; Rozemuller, J. M.; Stam, F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchrows Arch. B Cell Pathol. 56:259-262; 1989.
23. 23. Eikelenboom, P.; Rozemuller, J. M.; Kraal, G.; Stam, F. C.; McBride, P. A.; Bruce, M. E.; Fraser, H. Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchrows Arch. B Cell Pathol. 60:329-336; 1991.
24. 24. Eikelenboom, P.; Zhan, S. S.; van Gool, W. A.; Allsop, D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15:447-450; 1994.
25. 25. Eikelenboom, P.; Stam, F. C. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchrows Arch. B Cell Pathol. 47:17-25; 1984.
26. 26. Eikelenboom, P.; Zhan, S. S.; Kamphorst, W.; van der Valk, P.; Rozemuller, J. M. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer's disease. Virchrows Arch. 424:421-427; 1994.
27. 27. Fillit, H.; Ding, W.; Buee, L.; Kaiman, J.; Altstiel, L.; Lawlor, B.; Wolf-Klein, G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129:318-320; 1991.
28. 28. Forloni, G.; Demicheli, F.; Giorgi, S.; Bendotti, C.; Angeretti, N. Expression of amyloid precursor protein mRNAs, in endothelial, neuronal and glial cells: modulation by interleukin-1. Mol. Brain Res. 16:128-134; 1992.
29. 1-Antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 61:298-305; 1993.
30. 30. Frohman, E. M.; Frohman, T. C.; Gupta, S.; de Fougerolles, A.; van den Noort, E. Expression of intercellular adhesion molecule-1 (ICAM-1) in Alzheimer's disease. J. Neurol. Sci. 106:105-111; 1991.
31. 31. Gillian, A. M.; Brion, J.-P.; Breen, K. C. Expression of the neural cell adhesion molecule (NCAM) in Alzheimer's disease. Neurodegeneration 3:283-291; 1994.
32. 32. Gitter, B. D.; Cox, L. M.; Keith, P. T.; Rydel, R. E.; May. P. C. Amyloid beta peptide (Aβ) potentiates cytokine secretion by interleukin-1 activated human astrocytoma cells. Soc. Neurosci. Abstr. 19:832; 1993.
33. 33. Goldgaber, D.; Harris, H. W.; Hla, T.; Maciag, T.; Donnelly, R. J.; Jacobsen, J. S.; Vitek, M. P.; Gajdusek, C. Interleukin-1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA 86:7606-7610; 1989.
34. 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 3:201-203; 1992.
35. 35. Graves, A. B.; White, E.; Koepsell, T. D.; Reifler, B. V.; van Belle, G.; Larson, E. B.; Raskind, M. A case-control study of Alzheimer's disease. Ann. Neurol. 28:766-774; 1990.
36. 36. Gray, C. W.; Patel, A. J. Regulation of α-amyloid precursor protein isoform mRNAs by transforming growth factorβ-1 and interleukin-1β in astrocytes. Mol. Brain Res. 19:251-256; 1993.
37. 37. Griffin, W. S. T.; Stanley, L. C.; Ling, C.; White, L.; MacLeod, V.; Perrot, L. J.; White, C. L., III; Araoz, C. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 86:7611-7615; 1989.
38. 38. Hamazaki, H. Amyloid P component promotes aggregation of Alzheimer's beta-amyloid peptide. Biochem. Biophys. Res. Commun. 211:349-353; 1995.
39. 39. Haynes, R. C., Jr. Adrenocorticotropic hormone: Adrenocortical steroids and their synthetic analogs; Inhibitors of the synthesis and action of adrenocortical hormones. In: Gilman, A. G.; Rail, T. W.; Nies, A. S.; Taylor, P., eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press; 1990:1431-1462.
40. 40. Ishii, T.; Haga, S. Immuno-electron microscopic localization of immunoglobulins in amyloid fibrils of senile plaques. Acta Neuropathol. (Berl.) 36:243-249; 1976.
41. 41. Ishii, T.; Haga, S. Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol. (Berl.) 63:296-300; 1984.
42. 42. Ishii, T.; Haga, S.; Kametani, F. Presence of immunoglobulins and complements in the amyloid plaques in the brain of patients with Alzheimer's disease. In: Pouplard-Barthelaix, A.; Emile, J.; Christen, Y., eds. Immunology and Alzheimer's disease. Berlin: Springer Verlag; 1988:17-29.
43. 43. Ishii, T.; Haga, S.; Shimizu, F. Identification of components of immunoglobulins in senile plaques by means of fluorescent antibody technique. Acta Neuropathol. (Berl.) 32:157-162; 1975.
44. 44. Itagaki, S.; Akiyama, H.; Saito, H.; McGeer, P. L. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645:78-84; 1994.
45. 45. Itagaki, S.; McGeer, P. L.; Akiyama, H. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. J. Neuroimmunol. 24:173-182; 1989.
46. 46. Iwamoto, N.; Nishiyama, E.; Ohwada, J.; Arai, H. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: Immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci. Lett. 177:23-26; 1994.
47. 47. Jenkinson, M. I.; Bliss, M. R.; Brain, A. T.; Scott, D. L. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br. J. Rheumatol. 28:86-87; 1989.
48. 48. Jiang, H.; Burdick, D.; Glabe, C. G.; Cotman, C. W.; Tenner, A. J. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q chain. J. Immunol. 152:5050-5059; 1994.
49. 49. Johnson, S. A.; Lampert-Etchells, M.; Pasinetti, G. M.; Rozovsky, I.; Finch, C. E. Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiol. Aging 13:641-648; 1992.
50. 50. Kalaria, R. N. The immunopathology of Alzheimer' s disease and some related disorders. Brain Pathol. 3:333-347; 1993.
51. 51. Kalaria, R. N.; Kroon, S. N. Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer's disease. Biochem. Biophys. Res. Commun. 186:461-466; 1992.
52. 52. Katzman, R.; Terry, R.; DeTeresa, R.; Brown, T.; Davies, P.; Fuld, P.; Renbing, X.; Peck, A. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol, 23:138-144; 1988.
53. 53. Kisilevsky, R. Inflammation-associated amyloidogenesis: Lessons for Alzheimer's amyloidogenesis. Mol. Neurobiol. 8:65-66; 1994.
54. 54. Kowall, N. W.; McKee, A. C.; Yankner, B. A.; Beal, M. F. In vivo neurotoxicity of beta-amyloid [β(1-40)] and the β(25-35) fragment. Neurobiol. Aging 13:537-542; 1992.
55. 55. Kuby, J. Immunology. New York: W. H. Freeman and Company; 1994:393-411.
56. 56. Li, G.; Shen, Y. C.; Chen, C. H.; Zhau, Y. W.; Silverman; J. M. A case-control study of Alzheimer's disease in China. Neurology 42: 1481-1482; 1992.
57. 57. Luber-Narod, J.; Rogers, J. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci. Lett. 94:17-22; 1988.
58. 58. Lucca, U.; Tettamanti, M.; Forloni, G.; Spagnoli; A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol. Psychiatry 36:854-856; 1994.
59. 59. Lue, L.-F.; Rogers, J. Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3:308-313; 1992.
60. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372: 92-94; 1994.
61. 61. Mackenize, I. R. A.; McKelvie, P. A.; Beyreuther, K.; Masters, C. L. βA4 amyloid protein deposition in the cerebellum in Alzheimer's disease and Down's syndrome. Dementia 2:237-242; 1991.
62. 62. Mattiace, L. A.; Davies, P.; Dickson. D.W. Detection of HLA-DR on microglia in postmortem human brain is a function of clinical and technical factors. Am. J. Pathol. 136:1101-1114; 1990.
63. 63. May, P. C.; Boggs, L. N.; Fuson, K. S. Neurotoxicity of human amylin in rat primary hippocampal cultures: Similarity to Alzheimer's disease amyloid-β neurotoxicity. J. Neurochem. 61:1-4; 1993.
64. 64. May, P. C.; Finch, C. E. Sulfated glycoprotein 2: New relationships of this multifunctional protein to neurodegeneration. Trends Neurosci. 15:391-396; 1992.
65. 65. May, P. C.; Lamport-Etchells, M.; Johnson, S. A.; Poirier, J.; Masters, J. N.; Finch, C. E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 5:831-839; 1990.
66. 66. McGeer, P. L.; Akiyama, H.; Itagaki, S.; McGeer, E. G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:341-346; 1989.
67. 67. McGeer, P. L.; Akiyama, H.; Itagaki, S.; McGeer, E. G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:516-527; 1989.
68. 68. McGeer, P. L.; Harada, N.; Kimura, H.; McGeer, E. G.; Schulzer, M. Prevalence of dementia amongst elderly Japanese with leprosy: Apparent effect of chronic drug therapy. Dementia 3:146-149; 1992.
69. 69. McGeer, P. L.; Itagaki, S.; Tago, H.; McGeer, E. G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79:195-200; 1987.
70. 70. McGeer, P. L.; Kawamata, T.; Walker, D. G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 579:337-341; 1992.
71. 71. McGeer, P. L.; McGeer, E. G. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. (in press).
72. 72. McGeer, P. L.; Mcgeer, E. G.; Itagaki, S.; Mizukawa, K. Anatomy and pathology of the basal ganglia. Can. J. Neurol. Sci. 12:363-372; 1987.
73. 73. McGeer, P. L.; McGeer, E. G.; Rogers, J.; Sibley, J. Anti-inflammatory drugs and Alzheimer's disease. Lancet 335:1037; 1990.
74. 74. McGeer, P. L.; Walker, D. G.; Akiyama, H.; Kawamata, T.; Guan, A. L.; Parker, C. J.; Okada, N.; McGeer, E. G. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 544:315-319; 1991.
75. 75. Myllykangas-Luosujarvi, R.; Isomaki, H. Alzheimer's disease and rheumatoid arthritis. Br. J. Rheumatol. 33:501-502; 1994.
76. 76. Pike, C. J.; Walencewicz, A. J.; Glabe, C. G.; Cotman, C. W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 56:311-314; 1991.
77. 77. Rich, J. B.; Rasmusson, D. X.; Folstein, M. F.; Carson, K. A.; Kawas, C.; Brandt, J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45:51-55; 1995.
78. 78. Rogers, J.; Cooper, N. R.; Webster, S.; Schultz, J.; McGeer, P. L.; Styren, S. D.; Civin, W. H.; Brachova, L.; Bradt, B.; Ward, P.; Lieberburg. I. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 89:10016-10020; 1992.
79. 79. Rogers, J.; Kirby, L. C.; Hempelman, S. R.; Berry, D. L.; McGeer, P. L.; Kaszniak, A. W.; Zalinski, J.; Cofield, M.; Mansukhani, L.; Willson, P.; Kogan, F. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609-1611; 1993.
80. 80. Rogers, J.; Luber-Narod, J.; Styren, S. D.; Civin, W. H. Expression of immune system-associated antigen by cells of the human central nervous system. Relationship to the pathology of Alzheimer disease. Neurobiol. Aging 9:339-349; 1988.
81. 81. Rogers, J.; Singer, R. H.; Luber-Narod, J.; Bassell, G. J. Neurovirologic and neuroimmunologic considerations in Alzheimer's disease. Soc. Neurosci. Abstr. 12:944; 1986.
82. 82. Rozemuller, J. M.; Eikelenboom, P.; Pals, S. T.; Stam, F. C. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101:228-292; 1989.
83. 83. Rozemuller, J. M.; Stam, F. C.; Eikelenboom, P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci. Lett. 119:75-78; 1990.
84. 84. Sapolsky, R. M. Prolonged glucocorticoid exposure reduces hippocampal neuron number; Implications for aging. J. Neurosci. 5:1222-1227; 1985.
85. 85. Shalit, F.; Sredni, B.; Stern, L.; Kott, E.; Huberman, M. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci. Lett. 174:130-132; 1994.
86. 86. Schultz, J.; Schaller, J.; McKinley, M.; Bradt, B.; Cooper, N.; May, P.; Rogers, J. Enhanced cytotoxicity of amyloid β-peptide by a complement dependent mechanism. Neurosci. Lett. 175:99-102; 1994.
87. 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66:223-230; 1992.
88. 88. Styren, S. D.; Civin, W. H.; Rogers, J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer disease brain. Exp. Neurol. 110:93-104; 1990.
89. 89. Tennent, G. A.; Lovai, L. B.; Pepys, M. B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. USA 92:4299-4303; 1995.
90. 90. Tuohy, J. M.; Schultz, J. J.; Brachova, L.; Lue, L.-F.; Rogers, J. Evidence of increased levels of C4 binding protein in Alzheimer's disease. Soc. Neurosci. Abstr. 19:834; 1993.
91. 2-macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease. Neurobiol. Aging 14:233-237; 1993.
92. 92. Verbeek, M. M.; Otte-Holler, I.; Westphal, J. R.; Wesseling, P.; Ruiter, D. J.; de Waal, R. M. W. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am. J. Pathol. 144:104-116; 1994.
93. 93. Walker, D. G.; McGeer, P. L. Complement gene expression in human brain: Comparison between normal and Alzheimer disease cases. Mol. Brain Res. 14:109-106; 1992.
94. 94. Walker, D. G.; Yasuhara, O.; Patston, P. A.; McGeer, E. G.; McGeer, P. L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 675:75-82; 1995.
95. 95. Webster, S.; Glabe, C.; Rogers, J. Multivalent binding of complement protein C1q to the amyloid β-peptide promotes the nucleation phase of Aβ aggregation. Biochem. Biophys. Res. Commun. 217:869-875; 1995.
96. 96. Webster, S. D.; Lue, L.-F.; McKinley, M.; Rogers, J. Ultrastructural localization of complement proteins to neuronal membranes and β-amyloid peptide containing Alzheimer's disease pathology. Soc. Neurosci. Abstr. 18:765; 1992.
97. 97. Webster, S.; O'Barr, S.; Rogers, J. Enhanced aggregation and β structure of amyloid β peptide after co-incubation with C1q. J. Neurosci. Res. 39:448-456; 1994.
98. 98. Webster, S.; Rogers, J. Relative efficacies of amyloid peptide (Aβ) binding proteins in Aβ aggregation. J. Neurosci. Res. (in press).
99. 2-macroglobulin and C-reactive protein. Brain Res. 629:245-252; 1993.
100. 100. Yankner, B. A.; Duffy, L. K.; Kirschner, D. A. Neurotrophic and neurotoxic effects of amyloid-β protein: Reversal by tachykinin neuropeptides, Science 250:279-282; 1990.